Quinn Thibodeaux, MD
Dermatopathology · High Point, NCNPI 1245771575
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $915 of the $1,085 with a category attached, or 84.3%. 13 manufacturers reported payments, led by Ortho Dermatologics, A Division Of Bausch Health US, LLC at 34.8% of the total. Reporting peaked in 2019 at $462 and has fallen 73.9% since, to $121 in 2025.
Across 20 payments — averaging $54.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$377
- Galderma Laboratories, L.p.$188
- Johnson & Johnson$170
- Pfizer$113
- VYNE Pharmaceuticals Inc.$53
- Sanofi$39
- plus $146 from 7 others
What the payments were for
- Food & beverage$91584%
- Education$17016%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $377 |
| Galderma Laboratories, L.p. | 2 | $188 |
| Johnson & Johnson | 2 | $170 |
| Pfizer | 2 | $113 |
| VYNE Pharmaceuticals Inc. | 1 | $53 |
| Sanofi | 2 | $39 |
| Incyte Corporation | 1 | $28 |
| Botanix SB Inc | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Verrica Pharmaceuticals Inc. | 1 | $22 |
| LNHC, Inc | 1 | $18 |
| UCB, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUZU$237
How this compares
Too few dermatopathology providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 32 | $1,205 |
| Triamcinolone Acetonide | 28 | $438 |
| Ketoconazole | 30 | $332 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in High Point
- Jonathan YaoGreensboro$105K
- Rita Pichardo GeisingerWinston Salem$30K
- Paul KostuchenkoWinston Salem$13K
- Scott McClellanNew Bern$7K
- Jonathan MilesChapel Hill$5K
- Jennifer NguyenCharlotte$3K
- David GuillenGastonia$2K
- John PapalasGreenville$1K
- Daniel ZedekChapel Hill$890
- Earl GrossMorehead City$326
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.